A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis

NCT02561806 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

302

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

DRUG: Ixekizumab
DRUG: Ustekinumab
DRUG: Placebo

Sponsor

Eli Lilly and Company